Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.76 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.76 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6684058 | 0.86 | TGFBR1 (1.00) | TGFBR1MAPK14KDM4EALDH1A1RXFP1 | |
| SCHEMBL14731231 | 0.86 | TGFBR1 (0.70) | TGFBR1MAPK14TGFBR2KDM4E | |
| SCHEMBL16404298 | 0.74 | ABCG2 (0.72) | TGFBR1MAPK14KDM4EALDH1A1RXFP1 | |
| SCHEMBL2906534 | 0.73 | TGFBR1 (0.76) | TGFBR1MAPK14 | |
| SCHEMBL6122117 | 0.72 | KDM4E (0.57) | TGFBR1MAPK14KDM4EALDH1A1 | |
| SCHEMBL29721920 | 0.72 | TGFBR1 (0.59) | TGFBR1MAPK14TGFBR2 | |
| SCHEMBL28734419 | 0.72 | TGFBR1 (0.59) | TGFBR1MAPK14TGFBR2 | |
| SCHEMBL6682547 | 0.71 | TGFBR1 (1.00) | TGFBR1MAPK14TGFBR2ALDH1A1 | |
| SCHEMBL28734420 | 0.70 | TGFBR1 (0.57) | TGFBR1MAPK14TGFBR2 | |
| SCHEMBL12090562 | 0.69 | TGFBR1 (1.00) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | TGFBR1 4850/4885MAPK14 1943/4885TGFBR2 4845/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | TGFBR1 4780/4885MAPK14 1510/4885TGFBR2 4786/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | TGFBR1 4850/4885MAPK14 1943/4885TGFBR2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.